Adoptive  	Adoptive  	 JJ	B-NP
T-cell  	T-cell  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
of  	of  	 IN	O
cancer  	cancer  	 NN	O
Adoptive  	Adoptive  	 NNP	B-NP
immunotherapy  	immunotherapy  	 NN	I-NP
is  	is  	 VBZ	O
determined  	determined  	 VBN	O
as  	as  	 IN	O
the  	the  	 DT	O
isolation  	isolation  	 NN	O
of  	of  	 IN	O
antigen-specific  	antigen-specific  	 JJ	B-NP
cells 	cells 	 NNS	I-NP
,  	,  	 ,	O
their  	their  	 PRP$	O
ex  	ex  	 JJ	B-NP
vivo  	vivo  	 JJ	I-NP
expansion  	expansion  	 NN	I-NP
and  	and  	 CC	O
activation 	activation 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
subsequent  	subsequent  	 JJ	O
autologous  	autologous  	 JJ	B-NP
administration  	administration  	 NN	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
a  	a  	 DT	O
promising  	promising  	 JJ	O
approach  	approach  	 NN	O
to  	to  	 TO	O
inducing  	inducing  	 VB	O
antitumour  	antitumour  	 JJ	B-NP
immune  	immune  	 JJ	I-NP
responses 	responses 	 NNS	I-NP
.  	.  	 .	O
Identification  	Identification  	 NN	B-NP
of  	of  	 IN	I-NP
tumour  	tumour  	 JJ	I-NP
antigens  	antigens  	 NN	I-NP
and  	and  	 CC	O
monitoring  	monitoring  	 VBG	O
the  	the  	 DT	O
persistence  	persistence  	 NN	O
and  	and  	 CC	O
transport  	transport  	 NN	O
of  	of  	 IN	O
transferred  	transferred  	 JJ	O
cells  	cells  	 NNS	O
has  	has  	 VBZ	O
provided  	provided  	 VBN	O
our  	our  	 PRP$	O
understanding  	understanding  	 NN	O
over  	over  	 IN	O
the  	the  	 DT	O
mechanisms  	mechanisms  	 NNS	O
of  	of  	 IN	O
tumour  	tumour  	 JJ	B-NP
immunotherapy 	immunotherapy 	 NN	I-NP
.  	.  	 .	O
Cell-transfer  	Cell-transfer  	 JJ	B-NP
therapies  	therapies  	 NNS	I-NP
have  	have  	 VBP	O
seemed  	seemed  	 VBN	O
beneficial  	beneficial  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
selected  	selected  	 JJ	O
metastatic  	metastatic  	 JJ	B-NP
cancers  	cancers  	 NNS	I-NP
by  	by  	 IN	O
providing  	providing  	 VBG	O
a  	a  	 DT	O
blueprint  	blueprint  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
wider  	wider  	 JJR	O
application  	application  	 NN	O
of  	of  	 IN	O
adoptive  	adoptive  	 JJ	B-NP
cell  	cell  	 NN	I-NP
transfer  	transfer  	 NN	I-NP
( 	( 	 -LRB-	O
ACT 	ACT 	 NNP	B-NP
)  	)  	 -RRB-	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
emphasize  	emphasize  	 VB	O
the  	the  	 DT	O
requirement  	requirement  	 NN	O
for  	for  	 IN	O
in  	in  	 IN	O
vivo  	vivo  	 JJ	B-NP
persistence  	persistence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
cells  	cells  	 NNS	O
for  	for  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy 	efficacy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
magnitude  	magnitude  	 NN	O
and  	and  	 CC	O
specificity  	specificity  	 NN	O
of  	of  	 IN	O
immune  	immune  	 JJ	O
responses  	responses  	 NNS	O
to  	to  	 TO	O
pathogenic  	pathogenic  	 VB	O
organisms  	organisms  	 NNS	O
have  	have  	 VBP	O
let  	let  	 VB	O
a  	a  	 DT	O
search  	search  	 NN	O
for  	for  	 IN	O
ways  	ways  	 NNS	O
to  	to  	 TO	O
arm  	arm  	 VB	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
system  	system  	 NN	O
and  	and  	 CC	O
aim  	aim  	 VB	O
it  	it  	 PRP	O
at  	at  	 IN	O
a  	a  	 DT	O
specific  	specific  	 JJ	O
type  	type  	 NN	O
of  	of  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
Knowledge  	Knowledge  	 NN	O
of  	of  	 IN	O
immune  	immune  	 JJ	O
regulation  	regulation  	 NN	O
and  	and  	 CC	O
effector  	effector  	 JJ	B-NP
cell  	cell  	 NN	I-NP
function  	function  	 NNS	I-NP
have  	have  	 VBP	O
accumulated  	accumulated  	 VBN	O
rapidly  	rapidly  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
past  	past  	 JJ	O
decade  	decade  	 NN	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
incremental  	incremental  	 JJ	B-NP
gains  	gains  	 NNS	I-NP
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
manipulate  	manipulate  	 VB	O
host  	host  	 NN	B-NP
immunity  	immunity  	 NN	I-NP
and  	and  	 CC	O
specifically  	specifically  	 RB	O
target  	target  	 VB	O
tumour  	tumour  	 JJ	O
cells  	cells  	 NNS	O
for  	for  	 IN	O
immune  	immune  	 JJ	O
destruction 	destruction 	 NN	O
.  	.  	 .	O
Besides 	Besides 	 RB	O
,  	,  	 ,	O
converging  	converging  	 JJ	O
information  	information  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
fields  	fields  	 NNS	O
of  	of  	 IN	O
molecular  	molecular  	 JJ	B-NP
biology  	biology  	 NN	I-NP
and  	and  	 CC	O
cellular  	cellular  	 JJ	B-NP
immunology  	immunology  	 NN	I-NP
has  	has  	 VBZ	O
inspired  	inspired  	 VBN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
using  	using  	 VBG	O
potent  	potent  	 JJ	O
immunomodulators  	immunomodulators  	 NN	B-NP
and  	and  	 CC	O
molecularly  	molecularly  	 RB	O
defined  	defined  	 VBN	B-NP
immunogens 	immunogens 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
of  	of  	 IN	I-NP
immunotherapy  	immunotherapy  	 NN	I-NP
for  	for  	 IN	I-NP
treating  	treating  	 VBG	I-NP
cancer  	cancer  	 NN	I-NP
is  	is  	 VBZ	O
capitalizing  	capitalizing  	 VBG	O
on  	on  	 IN	O
these  	these  	 DT	O
advances 	advances 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
recent  	recent  	 JJ	O
efforts  	efforts  	 NNS	O
in  	in  	 IN	O
ACT  	ACT  	 NNP	B-NP
therapy  	therapy  	 NN	I-NP
provide  	provide  	 VB	O
an  	an  	 DT	O
excellent  	excellent  	 JJ	O
example  	example  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
progress 	progress 	 NN	O
.  	.  	 .	O
